Humanized anti-CLL-1 antibodies
Inventors
Jiang, Ying-Ping • Junutula, Jagath R. • Presta, Leonard G. • Tsurushita, Naoya
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are humanized antibodies specific for CLL-1.
Core Innovation
The invention provides an antibody that binds CLL-1, including a variable light chain comprising SEQ ID NO: 21 followed by further framework sequence SEQ ID NO: 22, and a variable heavy chain comprising SEQ ID NO: 23 followed by further framework sequence SEQ ID NO: 24. Humanized antibody repertoire variants are described as M26-derived and M31-derived variants with murine CDRs grafted onto human immunoglobulin frameworks, using defined SEQ ID-based variable light/heavy chain constructs.
The disclosed antibodies include defined human constant regions selected from IgG1, IgG2, IgG3, and IgG4, and include constant-region cysteine-substituted modification formats. The disclosed repertoire includes combinations of HuM26L4/HuM31VL variants with corresponding HuM31VH variants, and defined hinge-region and Fc format choices are described within the humanized framework context.
The disclosed antibody-related compositions further include conjugates and multi-specific formats in which CLL-1 binding is used for selective cytotoxicity. The document describes CDC and ADCC-enabled uses, as well as ADC and ADC conjugates using benzodiazepine-type cytotoxic payloads, and describes CAR constructs using CLL-1 binding domains. Selectivity is demonstrated as loss of effect in CLL-1 knockout and differential killing between quiescent and proliferating CLL-1+ cell conditions, including MDR+ve settings.
Claims Coverage
The independent claim is directed to a CLL-1-binding antibody defined by specific variable light-chain and variable heavy-chain sequence components, with multiple dependent claims refining the antibody’s constant region, format, and payload/conjugate features. The inventive features center on SEQ ID-defined variable light/heavy chain frameworks for CLL-1 binding, optional human constant-region selection and cysteine-substituted modification, and optional bi-specific targeting and benzodiazepine cytotoxic conjugation.
CLL-1-binding antibody with SEQ ID-defined variable light and variable heavy chains
An antibody that binds CLL-1, the antibody comprising a variable light chain comprising SEQ ID NO: 21 followed by further framework sequence SEQ ID NO: 22; and a variable heavy chain comprising SEQ ID NO: 23 followed by further framework sequence SEQ ID NO: 24.
Human constant region selected from IgG1 to IgG4
The antibody additionally comprises a human constant region selected from IgG1, IgG2, IgG3, and IgG4.
Constant region cysteine-substituted modification
The antibody is an antibody with a constant region cysteine-substituted modification.
Bi-specific antibody with a defined second target antigen set
A bi-specific antibody is provided that has a first arm binding CLL-1 and a second arm that binds a second target antigen selected from CD33, CD123, IL1Rap, GPR114, or CD3 on T cells.
scFv region-containing antibody format
The antibody includes an scFv region.
Benzodiazepine cytotoxic agent for the conjugate
The cytotoxic agent is a benzodiazepine.
Across the independent and dependent claim set provided, the core coverage is a CLL-1-binding antibody defined by SEQ ID NO:21/22 (variable light) and SEQ ID NO:23/24 (variable heavy), with further coverage for specified human constant-region classes, cysteine-substituted constant-region modifications, optional scFv formatting and bi-specific second-target selection, and conjugates that use a benzodiazepine cytotoxic agent.
Stated Advantages
Selective killing is described in connection with CLL-1-dependent cytotoxicity, including loss of effect in CLL-1 knockout cells and differential killing between quiescent and proliferating CLL-1+ cell conditions.
Activity is described in MDR+ve settings.
Documented Applications
CDC and ADCC uses enabled by a CLL-1 binding antibody.
ADC/antibody-drug conjugate conjugates using benzodiazepine-type cytotoxic payloads for CLL-1-dependent cytotoxicity, including MDR+ve settings.
CAR constructs using CLL-1 binding domains.
Bi-specific antibodies having a first arm binding CLL-1 and a second arm binding a second target antigen selected from CD33, CD123, IL1Rap, GPR114, or CD3 on T cells.
Interested in licensing this patent?